<p>Cells were exposed 24 h to oxaliplatin (OXA) (2–200 µM). P2X7 receptor activation (A) was evaluated using YOPRO-1 test. The resulting fluorescence was viewed with a microscope (B). Chromatin condensation (C) was evaluated using Hoechst 33342 test. Caspase-3 proteolytic activity (D) in lysates of cells was evaluated using the apoTarget<sup>TM</sup> Caspase-3 Protease assay. In these tests, cells were exposed or not to a 30-min pre-treatment with the specific P2X7 receptor antagonist Brilliant Blue G (BBG; 10 µM) prior to OXA for an additional 24 h. Values are the mean ± S.E.M. expressed as percentage of the control, five different assays per group. *: statistically different (p<0.05) from the mean values in control cells.</p
In attempts to develop an orally applicable platinum-based drug, platinum(IV) drugs which exhibit hi...
<p>Cells (2×10<sup>5</sup> cells/well) were exposed 24 h to oxaliplatin (OXA) (2–200 µM). Cell viabi...
L'oxaliplatine est un médicament anticancéreux utilisé dans la chimiohyperthermie intrapéritonéale (...
<p>P2X7 receptor (P2X7R) activation was evaluated using YOPRO-1 test and chromatin condensation usin...
<p>Cells (2×10<sup>5</sup> cells/well) were exposed for 24 h to oxaliplatin (OXA) (50, 100 or 200 µM...
<p>Mice were repeatedly injected i.p. with 7 mg/kg oxaliplatin (OXA) at days 1, 2, 5 and 6 (28 mg/kg...
Limited information is available regarding the cellular mechanisms of oxaliplatin-induced painful ne...
The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the t...
<p>A) MMP7 expression was inhibited by siRNA and then treated with different doses of oxaliplatin in...
<p>SH-SY5Y cells and RAW 264.7 cells were exposed 24 h to oxaliplatin (OXA) (200 µM) with a 30-min p...
<p>A) Immunofluorescence (IF) staining of MMP7 in the non-resistant (HT29, HCT116 p53<sup>+/+</sup>,...
BACKGROUND: Time-dependence of cisplatin (CDDP) and oxaliplatin (L-OHP) cytotoxic effects in A431 a...
The YO-PRO-1 assay provides a quantitative estimation of P2X7 receptor activation. P2X7 receptor is ...
This study measures the time-dependence of cellular caspase activation by anticancer drugs and compa...
<p>Cells (2×10<sup>5</sup> cells/well) were exposed for 24 h to oxaliplatin (OXA) (50, 100 or 200 µM...
In attempts to develop an orally applicable platinum-based drug, platinum(IV) drugs which exhibit hi...
<p>Cells (2×10<sup>5</sup> cells/well) were exposed 24 h to oxaliplatin (OXA) (2–200 µM). Cell viabi...
L'oxaliplatine est un médicament anticancéreux utilisé dans la chimiohyperthermie intrapéritonéale (...
<p>P2X7 receptor (P2X7R) activation was evaluated using YOPRO-1 test and chromatin condensation usin...
<p>Cells (2×10<sup>5</sup> cells/well) were exposed for 24 h to oxaliplatin (OXA) (50, 100 or 200 µM...
<p>Mice were repeatedly injected i.p. with 7 mg/kg oxaliplatin (OXA) at days 1, 2, 5 and 6 (28 mg/kg...
Limited information is available regarding the cellular mechanisms of oxaliplatin-induced painful ne...
The platinum compound oxaliplatin has been shown to be an effective chemotherapeutic agent for the t...
<p>A) MMP7 expression was inhibited by siRNA and then treated with different doses of oxaliplatin in...
<p>SH-SY5Y cells and RAW 264.7 cells were exposed 24 h to oxaliplatin (OXA) (200 µM) with a 30-min p...
<p>A) Immunofluorescence (IF) staining of MMP7 in the non-resistant (HT29, HCT116 p53<sup>+/+</sup>,...
BACKGROUND: Time-dependence of cisplatin (CDDP) and oxaliplatin (L-OHP) cytotoxic effects in A431 a...
The YO-PRO-1 assay provides a quantitative estimation of P2X7 receptor activation. P2X7 receptor is ...
This study measures the time-dependence of cellular caspase activation by anticancer drugs and compa...
<p>Cells (2×10<sup>5</sup> cells/well) were exposed for 24 h to oxaliplatin (OXA) (50, 100 or 200 µM...
In attempts to develop an orally applicable platinum-based drug, platinum(IV) drugs which exhibit hi...
<p>Cells (2×10<sup>5</sup> cells/well) were exposed 24 h to oxaliplatin (OXA) (2–200 µM). Cell viabi...
L'oxaliplatine est un médicament anticancéreux utilisé dans la chimiohyperthermie intrapéritonéale (...